IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0663314
(2005-09-19)
|
등록번호 |
US-8771754
(2014-07-08)
|
국제출원번호 |
PCT/US2005/033504
(2005-09-19)
|
§371/§102 date |
20080910
(20080910)
|
국제공개번호 |
WO2006/034207
(2006-03-30)
|
발명자
/ 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
Jenkins, Wilson, Taylor & Hunt, P.A.
|
인용정보 |
피인용 횟수 :
3 인용 특허 :
0 |
초록
▼
The presently disclosed subject matter relates generally to the fields of molecular biology and medicine. More particularly, it concerns methods involving the use of GSK3 inhibitors in combination with radiation therapies. In some embodiments, administration of a GSK3 inhibitor to a subject results
The presently disclosed subject matter relates generally to the fields of molecular biology and medicine. More particularly, it concerns methods involving the use of GSK3 inhibitors in combination with radiation therapies. In some embodiments, administration of a GSK3 inhibitor to a subject results in an amelioration of cognitive decline, toxicity to vascular endothelial cells, and/or neuron death associated with radiation therapy alone.
대표청구항
▼
1. A method for treating a hyperproliferative disease in a subject comprising administering radiation therapy in combination with a pharmaceutical composition comprising an inhibitor of glycogen synthase kinase 3 (GSK3) comprising lithium or a pharmaceutically acceptable salt thereof to the subject,
1. A method for treating a hyperproliferative disease in a subject comprising administering radiation therapy in combination with a pharmaceutical composition comprising an inhibitor of glycogen synthase kinase 3 (GSK3) comprising lithium or a pharmaceutically acceptable salt thereof to the subject, wherein the inhibitor of GSK3 is administered to the subject prior to and during administration of the radiation therapy, and in an amount and via a route effective to protect a cell selected from the group consisting of a neuron, a vascular endothelial cell, a salivary gland cell, a gastrointestinal tract cell, a lung cell, and a liver cell from radiation-induced apoptosis. 2. The method of claim 1, wherein the subject is a mammal. 3. The method of claim 2, wherein the mammal is a human. 4. The method of claim 1, wherein the GSK3 inhibitor is administered in a pharmaceutically acceptable carrier, diluent, or vehicle. 5. The method of claim 1, wherein the GSK3 inhibitor is administered to the subject intranasally, intradermally, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostaticaly, intrapleurally, intratracheally, intravitreally, intravaginally, intrarectally, topically, intratumorally, intramuscularly, intraperitoneally, subcutaneously, subconjunctivally, intravesicularlly, mucosally, intrapericardially, intraumbilically, intraocularally, orally, locally, via inhalation, via injection, via infusion, via continuous infusion, via localized perfusion to a tumor, by bathing target cells directly, via a catheter, via a lavage, in a creme, in a lipid composition, or by any combination of the forgoing. 6. The method of claim 5, wherein the tumor comprises a cancerous tumor. 7. The method of claim 6, wherein the tumor comprises a brain tumor. 8. The method of claim 6, wherein the tumor comprises a lung tumor. 9. The method of claim 1, wherein the hyperproliferative disease is selected from the group consisting of a benign tumor, an arteriovenous malformation, a neuroma, a meningioma, a schwanoma, an adenoma, a glioma, and combinations thereof. 10. The method of claim 9, wherein the neuroma comprises an acoustic neuroma or an optic neuroma. 11. The method of claim 9, wherein the adenoma comprises a pituitary adenoma. 12. The method of claim 9, wherein the glioma comprises an optic glioma. 13. The method of claim 9, wherein the benign tumor is selected from the group consisting of a brain tumor, a spinal cord tumor, an eye tumor, and a lung tumor. 14. The method of claim 1, wherein the hyperproliferative disease comprises cancer. 15. The method of claim 14, wherein the cancer is selected from the group consisting of lung cancer, prostate cancer, ovarian cancer, testicular cancer, brain cancer, skin cancer, colon cancer, gastric cancer, esophageal cancer, tracheal cancer, head and neck cancer, pancreatic cancer, liver cancer, breast cancer, ovarian cancer, lymphoid cancer, leukemia, cervical cancer, vulvar cancer, and cancer of the eye. 16. The method of claim 15, wherein the cancer comprises brain cancer. 17. The method of claim 15, wherein the cancer comprises lung cancer. 18. The method of claim 14, wherein the radiation therapy comprises cranial radiation therapy. 19. The method of claim 14, wherein the administering comprises administering a sufficient amount of the GSK3 inhibitor to result in a reduction in toxicity associated with the radiation therapy to a neuron. 20. The method of claim 19, wherein the neuron comprises a neuron of the central nervous system. 21. The method of claim 20, wherein the neuron is a hippocampal neuron. 22. The method of claim 19, wherein the neuron comprises a neuron of the peripheral nervous system. 23. The method of claim 19, wherein the toxicity comprises neuron death. 24. The method of claim 19, wherein the toxicity comprises apoptosis. 25. The method of claim 18, wherein the administering comprises administering a sufficient amount of the GSK3 inhibitor to result in a reduction in cognitive decline of the subject associated with the cranial radiation therapy. 26. The method of claim 18, wherein the administering comprises a sufficient amount of the GSK3 inhibitor to result in a reduction in toxicity associated with the cranial radiation therapy to non-neuronal cells. 27. The method of claim 26, wherein the non-neuronal cells are vascular endothelial cells. 28. The method of claim 26, wherein the non-neuronal cells are salivary gland cells, gastrointestinal tract cells, lung cells, liver cells, or vascular endothelial cells. 29. The method of claim 28, wherein the toxicity comprises death of the cells. 30. The method of claim 28, wherein the toxicity comprises apoptosis of the cells. 31. The method of claim 28, wherein the reduction of toxicity comprises an elimination of toxicity. 32. The method of claim 1, further comprising administering a second pharmaceutical composition. 33. The method of claim 32, wherein the second pharmaceutical composition comprises an anti-cancer composition. 34. The method of claim 1, wherein the inhibitor of GSK3 is administered to the subject beginning about 7 days prior to the administration of the radiation therapy. 35. The method of claim 34, wherein the inhibitor of GSK3 is administered daily to the subject beginning about 7 days prior to the administration of the radiation therapy.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.